CinCor Pharma, Inc. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
19CinCor Pharma's Business Model
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
About CinCor Pharma
Website: https://www.cincor.com
CEO (Chief Executive Officer): Mr. Marc M. P. de Garidel
IPO date: 2022-01-07
Contact
Country: US
Address: 200 Clarendon Street
City: Boston
State: MA
Phone: 844 531 1834
Zip Code: 02116
Other
CIK: 0001868734
ISIN: US17240Y1091
CUSIP: 17240Y109
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
